CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CURIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.38−0.03 (-6.26%)
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 2M shares
Institutional holders
1
1 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $5.50K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wilmot B. Harkey | 4,215,165 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Stonepine Capital, L.P. | 4,025,992 | 9.90% | 13G (passive) | Mar 17, 2026 |
| Thomas A. Satterfield, Jr. | 3,957,950 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Nantahala Capital Partners Limited Partnership | 2,944,000 | 6.98% | 13G (passive) | Mar 31, 2026 |
| Armistice Capital, LLC | 1,336,876 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Bleichroeder LP | 1,035,662 | 9.90% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRIS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 15 | 0.00% | $8 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James E. Dentzer | President & CEO, Director | 148,730 | 7.12% | Jul 9, 2026 |
| Jonathan B. Zung | CDO | 66,667 | 3.19% | Jul 9, 2026 |
| Diantha Duvall | CFO | 77,707 | 3.72% | Jul 9, 2026 |
| Ahmed Hamdy MD | CMO | 66,667 | 3.19% | Mar 23, 2026 |
| John Hohneker | Director | – | – | Jul 9, 2026 |
| Martyn D. Greenacre | Director | 26,089 | 1.25% | Jul 9, 2026 |
| Kenneth I. Kaitin | Director | 11,407 | 0.55% | Jul 9, 2026 |
| Anne Elizabeth Borgman | Director | – | – | Jul 9, 2026 |
| Marc Rubin | Director | 28,108 | 1.34% | Jul 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kenneth I. Kaitin Director | Mar 31, 2026 | Buy | +10,000 | $0.55 | $5.50K | 11,407 |
| Jonathan B. Zung CDO | Mar 20, 2026 | Conversion | +66,667 | – | – | 66,667 |
| Ahmed Hamdy MD CMO | Mar 20, 2026 | Conversion | +66,667 | – | – | 66,667 |
| James E. Dentzer President & CEO, Director | Mar 20, 2026 | Conversion | +133,333 | – | – | 148,730 |
| Diantha Duvall CFO | Mar 20, 2026 | Conversion | +66,666 | – | – | 77,707 |
| Marc Rubin Director | Mar 20, 2026 | Conversion | +26,667 | – | – | 28,108 |
| James E. Dentzer President & CEO, Director | Jan 31, 2022 | Sale(10b5-1 plan) | −3,094 | $3.07 | $9.50K | 64,877 |
| James E. Dentzer President & CEO, Director | Jan 27, 2022 | Sale(10b5-1 plan) | −2,406 | $3.18 | $7.65K | 67,971 |
| James E. Dentzer President & CEO, Director | Jan 26, 2021 | Sale(10b5-1 plan) | −3,094 | $10.59 | $32.77K | 67,268 |
| James E. Dentzer President & CEO, Director | Jan 25, 2021 | Sale(10b5-1 plan) | −2,283 | $10.96 | $25.02K | 70,362 |
| James E. Dentzer President & CEO, Director | Jan 24, 2020 | Sale(10b5-1 plan) | −3,094 | $1.64 | $5.07K | 42,158 |
| James E. Dentzer President & CEO, Director | Jan 23, 2020 | Sale(10b5-1 plan) | −3,658 | $1.69 | $6.18K | 45,252 |
| James E. Dentzer President & CEO, Director | Jan 24, 2019 | Sale(10b5-1 plan) | −3,094 | $1.16 | $3.59K | 41,639 |
| Kenneth I. Kaitin Director | Jan 23, 2019 | Sale(10b5-1 plan) | −14,800 | $1.05 | $15.54K | 28,121 |
| Marc Rubin Director | Jan 23, 2019 | Sale(10b5-1 plan) | −18,500 | $1.05 | $19.43K | 28,819 |
| James E. Dentzer President & CEO, Director | Jan 23, 2019 | Sale(10b5-1 plan) | −2,397 | $1.09 | $2.61K | 44,733 |
| Robert Martell Head of Research & Development | Jan 23, 2019 | Sale(10b5-1 plan) | −5,500 | $1.07 | $5.89K | 23,027 |
| Robert Martell Head of Research & Development | Jan 23, 2019 | Tax withholding | −8,473 | $1.07 | $9.07K | 28,527 |
| Martyn D. Greenacre Director | Jan 23, 2019 | Sale(10b5-1 plan) | −18,500 | $1.05 | $19.43K | 26,089 |
| Lori Anne Kunkel Director | Jan 23, 2019 | Sale(10b5-1 plan) | −14,800 | $1.05 | $15.54K | 22,200 |
| Lori Anne Kunkel Director | Jan 22, 2018 | Award | +185,000 | – | – | 185,000 |
| Kenneth I. Kaitin Director | Jan 22, 2018 | Award | +185,000 | – | – | 214,607 |
| Marc Rubin Director | Jan 22, 2018 | Award | +185,000 | – | – | 236,596 |
| Robert Martell Director | Jan 22, 2018 | Award | +185,000 | – | – | 185,000 |
| James E. Dentzer Chief Financial Officer | Jan 22, 2018 | Award | +206,250 | – | – | 212,011 |
| Martyn D. Greenacre Director | Jan 22, 2018 | Award | +185,000 | – | – | 222,945 |
| Ali Ph.D. Fattaey President & CEO, Director | Jan 22, 2018 | Award | +206,250 | – | – | 322,140 |
| David Tuck Chief Medical Officer | Jan 22, 2018 | Award | +133,750 | – | – | 169,424 |
| Marc Rubin Director | Nov 16, 2017 | Buy | +25,000 | $0.98 | $24.50K | 51,596 |
| Ali Ph.D. Fattaey President & CEO, Director | Nov 15, 2017 | Buy | +50,000 | $1.06 | $53.00K | 115,890 |
| Kenneth I. Kaitin Director | May 31, 2017 | Tax withholding | −12,193 | $1.71 | $20.85K | 29,607 |
| Kenneth I. Kaitin Director | May 31, 2017 | Option exercise | +10,000 | $1.39 | $13.90K | 36,800 |
| Kenneth I. Kaitin Director | May 31, 2017 | Option exercise | +5,000 | $1.39 | $6.95K | 41,800 |
| Martyn D. Greenacre Director | May 31, 2017 | Tax withholding | −12,193 | $1.71 | $20.85K | 37,945 |
| Martyn D. Greenacre Director | May 31, 2017 | Option exercise | +5,000 | $1.39 | $6.95K | 50,138 |
| Martyn D. Greenacre Director | May 31, 2017 | Option exercise | +10,000 | $1.39 | $13.90K | 45,138 |
| James R. McNab Director | May 5, 2017 | Sale(10b5-1 plan) | −16,176 | $1.90 | $30.73K | 50,000 |
| James R. McNab Director | May 5, 2017 | Sale(10b5-1 plan) | −16,176 | $1.90 | $30.73K | 50,000 |
| James R. McNab Director | May 4, 2017 | Sale(10b5-1 plan) | −30,100 | $1.97 | $59.30K | 66,176 |
| James R. McNab Director | May 4, 2017 | Sale(10b5-1 plan) | −30,100 | $1.97 | $59.30K | 66,176 |
| James R. McNab Director | May 3, 2017 | Sale(10b5-1 plan) | −30,000 | $2.18 | $65.40K | 96,276 |
| James R. McNab Director | May 3, 2017 | Sale(10b5-1 plan) | −30,000 | $2.18 | $65.40K | 96,276 |
| James R. McNab Director | May 2, 2017 | Sale(10b5-1 plan) | −35,646 | $2.31 | $82.34K | 126,276 |
| James R. McNab Director | May 1, 2017 | Sale(10b5-1 plan) | −38,113 | $2.38 | $90.71K | 161,922 |
| James R. McNab Director | Apr 28, 2017 | Sale(10b5-1 plan) | −42,949 | $2.45 | $105.23K | 200,035 |
| James R. McNab Director | Apr 27, 2017 | Sale(10b5-1 plan) | −37,202 | $2.57 | $95.61K | 242,984 |
| James R. McNab Director | Apr 26, 2017 | Sale(10b5-1 plan) | −32,738 | $2.65 | $86.76K | 879,688 |
| James R. McNab Director | Apr 26, 2017 | Sale(10b5-1 plan) | −19,814 | $2.65 | $52.51K | 280,186 |
| James R. McNab Director | Apr 25, 2017 | Sale(10b5-1 plan) | −56,940 | $2.60 | $148.04K | 912,426 |
| James R. McNab Director | Apr 24, 2017 | Sale(10b5-1 plan) | −42,076 | $2.56 | $107.71K | 969,366 |
| James R. McNab Director | Apr 24, 2017 | Sale(10b5-1 plan) | −42,076 | $2.56 | $107.71K | 1,269,366 |
| James R. McNab Director | Apr 21, 2017 | Sale(10b5-1 plan) | −45,705 | $2.58 | $117.92K | 1,011,442 |
| James R. McNab Director | Apr 21, 2017 | Sale(10b5-1 plan) | −45,705 | $2.58 | $117.92K | 1,311,442 |
| James R. McNab Director | Apr 20, 2017 | Sale(10b5-1 plan) | −22,541 | $2.66 | $59.96K | 1,057,147 |
| James R. McNab Director | Apr 20, 2017 | Sale(10b5-1 plan) | −22,541 | $2.66 | $59.96K | 1,357,147 |
| Reddy's Holdings Ltd Dr. 10% owner | Sep 7, 2016 | Buy | +10,208,333 | $2.40 | $24.50M | 27,328,464 |
| Martyn D. Greenacre Director | May 27, 2016 | Sale | −5,000 | $1.69 | $8.45K | 35,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Option exercise | +5,000 | $1.67 | $8.35K | 40,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Option exercise | +10,000 | $1.67 | $16.70K | 45,183 |
| Martyn D. Greenacre Director | May 27, 2016 | Sale | −10,000 | $1.69 | $16.90K | 35,183 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.